Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.35 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.33 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820124 | 0.98 | CYP1A2 (0.38) | CYP1A2CYP2A6ALDH1A1MEN1KMT2A | |
| SCHEMBL29672565 | 0.95 | CYP1A2 (0.36) | CYP1A2CYP2A6ALDH1A1MEN1KMT2A | |
| Iodide SCHEMBL28719254 | 0.95 | KDM4E (0.38) | CYP1A2CYP2A6ALDH1A1MEN1KMT2A | |
| SCHEMBL22427651 | 0.86 | MAPT (0.36) | CYP2A6ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL20006913 | 0.86 | SMN1; SMN2 (0.41) | ALDH1A1MEN1KMT2AACHETSHR | |
| SCHEMBL16545308 | 0.80 | TSHR (0.44) | CYP1A2ALDH1A1TSHRCA1CA2 | |
| SCHEMBL20434169 | 0.80 | MEN1 (0.30) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL925633 | 0.76 | HTR2A (0.32) | HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL1155766 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AACHETSHR | |
| SCHEMBL8336707 | 0.73 | EPHB4 (0.33) | KMT2AKDM4ETDP1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114644661-B | Imidazole carbene iron complex and application thereof | 北京服装学院 | 2023-10-13 | — | — | CN | disclosed |
| EP-2574187-B1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | AMYRIS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-8586814-B2 | Squalane and isosqualane compositions and methods for preparing the same | Amyris, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2574187-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Amyris Biotechnologies, Inc. (US) | 2013-04-03 | — | — | EP | disclosed |
| WO-2011146837-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Amyris, Inc. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110287988-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | EUAGORE, LLC | 2011-11-24 | — | — | US | disclosed |
| US-7964758-B2 | Process for production of 2-(substituted phenyl)-3,3,3-trifluoropropene compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7883785-B2 | 5'-mono-, 5',5''-bis- and 5',5'',5'''-tris-aryl/heteroaryl-functionalized tris-orthometallated organorhodium and organoiridium compounds; readily soluble triplet emitters | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20100160683-A1 | Process for Production of 2-(Substituted Phenyl)-3,3,3-Trifluoropropene Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7534853-B2 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-7094897-B2 | Rhodium and iridium complexes | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2006-08-22 | — | — | US | disclosed |
| US-20060127696-A1 | Rhodium and iridium complexes | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20060065890-A1 | Rhodium and iridium complexes | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2006-03-30 | — | — | US | disclosed |
| US-20040133004-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287988-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | SQLE, FDFT1, COASY | ACHE 63/4885CA2 3667/4885GAA 689/4885 |
| US-20060065890-A1 | Rhodium and iridium complexes | RPIA, INPP5B, SIRT5 | ACHE 693/4885CA2 369/4885GAA 865/4885 |
| US-20100160683-A1 | Process for Production of 2-(Substituted Phenyl)-3,3,3-Trifluoropropene Compound | PEX3, SCO2, LPO | ACHE 4021/4885CA2 42/4885GAA 3727/4885 |
| US-20040133004-A1 | Rhodium and iridium complexes | RPIA, SIRT5, INPP5B | ACHE 830/4885CA2 415/4885GAA 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.